未登录

Q

Qiaozhi Cao

Central South University

H指数:3

被引数:40

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Ivarmacitinib provides rapid and continuous improvement in patients with moderate-to-severe atopic dermatitis: a focus on different anatomical regions

Ivarmacitinib可显著改善中重度特应性皮炎患者的症状，且效果快速且持续：重点关注不同解剖区域。

Inflammopharmacology

IF5.3

2025-12-150

PRE

The Incidence of Addiction and Its Risk Factors in Chinese Chronic Urticaria Patients

中国慢性荨麻疹患者中成瘾的发生率及其风险因素

CLINICAL AND EXPERIMENTAL ALLERGY

IF5.2

2025-09-010

PRE

Effectiveness and safety of dupilumab in moderate-to-severe atopic dermatitis patients with chronic renal insufficiency: a real-world retrospective study in China

IF10.7

2024-09-200

OA

Real-world effectiveness and safety of Janus kinase 1 inhibitors for the treatment of moderate-to-severe atopic dermatitis: a single-center, prospective study in China

FRONTIERS OF MEDICINE

IF3.5

2024-07-160

PRE

Atopic Dermatitis and Psoriasis: Similarities and Differences in Metabolism and Microbiome

特应性皮炎和银屑病: 代谢和微生物组的异同

CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY

IF11.3

2024-07-021

PRE

Predictive features for effectiveness of dupilumab in elderly patients with atopic dermatitis: a real-world study

BRITISH JOURNAL OF DERMATOLOGY

IF9.6

2024-07-020

PRE

Baseline eosinophil level may be a predictive indicator for the effectiveness of dupilumab in patients with prurigo nodularis: A single-center, real-world prospective study

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

IF11.8

2024-05-012

PRE

Dupilumab therapy in children aged 2-12?years with uncontrolled moderate-to-severe atopic dermatitis: A Chinese real-world study

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

IF8

2023-08-246

PRE